Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) announced that on December 1, 2025 it granted inducement restricted stock unit awards to two newly hired employees under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards total an aggregate of 2,200 restricted stock units, each representing the contingent right to one share of common stock. The RSUs vest in four equal annual installments beginning December 1, 2026, and vesting is conditioned on continued employment and the terms of each award agreement.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PCRX gained 0.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves (COLL -1.23%, DVAX -0.82%, AMPH +0.35%, AVDL -0.37%, HROW +1.98%), suggesting stock-specific trading rather than a broad sector trend for PCRX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Inducement equity awards | Neutral | +0.5% | Small RSU grants to two new employees under inducement plan. |
| Dec 02 | Clinical study update | Positive | +1.6% | 12‑month pilot showed better pain and function with iovera° vs RFA. |
| Nov 26 | Patent litigation | Negative | -1.0% | EXPAREL® patent infringement lawsuits filed against two counterparties. |
| Nov 11 | Conference participation | Neutral | +4.5% | Planned fireside chats at two major healthcare investor conferences. |
| Nov 10 | Activist involvement | Neutral | +4.5% | Investor letter urging board to explore a potential sale of business. |
Recent PCRX headlines, including clinical data, litigation, conferences, activism and equity grants, have generally seen share-price moves aligned with the apparent tone of each event.
Over the last month, Pacira reported pilot data for iovera° showing improved pain and function at multiple time points, a positive catalyst that preceded a 1.56% gain. Litigation over EXPAREL® patents, conference participation, and an activist letter calling for a potential sale all drew aligned price reactions, including two events with moves of 4.55%. Today’s inducement grants for 2,200 RSUs fit into this pattern of frequent corporate and clinical updates with generally aligned market responses.
Market Pulse Summary
This announcement details standard inducement grants totaling 2,200 restricted stock units to two new employees under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years and are conditioned on continued employment. In the broader context, Pacira recently reported rising quarterly revenue of $179.5M and net income of $5.4M, while also managing patent litigation and activist interest. Investors may watch future filings, clinical updates, and insider activity to gauge how governance and strategy evolve.
Key Terms
Nasdaq Listing Rule 5635(c)(4) regulatory
restricted stock units financial
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on December 1, 2026.
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
| Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com | Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com |
FAQ
What did Pacira (PCRX) disclose about inducement awards on December 3, 2025?
How do the PCRX restricted stock units vest and when is the first vesting date?
Were Pacira's inducement awards approved by shareholders for PCRX?
How many employees received awards and how many shares do the PCRX RSUs represent?
What conditions must be met for PCRX RSU vesting to occur?
